Tirofiban (hydrochloride hydrate) – 5 mg

Brand:
Cayman
CAS:
150915-40-5
Storage:
-20
UN-No:
Non-Hazardous - /

Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; IC50 = 5 nM in a radioligand binding assay).{37214} It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 μg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis.{37215} Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.{37216}  

 

Available on backorder

SKU: 23392 - 5 mg Category:

Description

A GPIIb/IIIa antagonist (IC50 = 5 nM in a radioligand binding assay); inhibits GPIIb/IIIa-dependent platelet aggregation (IC50 = 11 nM); inhibits HUVEC attachment to microtiter plates containing Fg, Vn, or Fn at concentrations >10,000-fold above the IC50 for platelet aggregation; prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis


Formal name: N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, monohydrochloride, monohydrate

Synonyms: 

Molecular weight: 495.1

CAS: 150915-40-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Blood|Acute Phase Reactants||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Blood|Thrombosis||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Vasculature|Angiogenesis